ArticleJournal of the advanced practitioner in oncology2021
A Pharmacist-Led Oral Chemotherapy Program's Impact on Chronic Myeloid Leukemia Patient Satisfaction, Adherence, and Outcomes.
Article in Journal of the advanced practitioner in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Adherence to oral antineoplastic agents, an overview and meta-analysis.The oncologist · 2026Pooled it
- The effect of healthcare professional-implemented interventions on adherence to oral targeted therapy in patients with cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Nurse and pharmacist systemic anti-cancer therapy review clinics and their impact on patient experience and care: A systematic review.Journal of advanced nursing · 2023Pooled it
- The impact of early oral anticancer medication monitoring through electronic patient assessments.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Trial
- Design and implementation of a risk-adapted, longitudinal, theory-driven medication adherence intervention: A protocol for a multi-phasic, hybrid effectiveness-implementation trial.Research in social & administrative pharmacy : RSAP · 2025Article
- Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative.Journal of managed care & specialty pharmacy · 2024Article
- Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report.Medicina (Kaunas, Lithuania) · 2024Article
- Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste.Journal of managed care & specialty pharmacy · 2024Article
- Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China.Frontiers in oncology · 2023Article
- Article
- Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy.JCO oncology practice · 2022Article
- Domains of Structured Oral Anticancer Medication Programs: A Scoping Review.Oncology nursing forum · 2022Article
- ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications.Oncology nursing forum · 2022Article
- Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review.Patient preference and adherence · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic myeloid leukemia (CML) can be treated with oral tyrosine kinase inhibitors (TKIs). Pharmacist-led oral chemotherapy programs (POCPs) can improve TKI adherence rates, but evaluation of patient satisfaction with such programs is rare. The purpose of this analysis was to compare the satisfaction of patients with CML taking TKIs enrolled in a POCP program with that of those not enrolled. Secondary objectives were to assess adherence rates, patient-reported value, early molecular response (EMR) rates, and major molecular response (MMR) rates. This study utilized an anonymous telephone survey of patients who had taken TKIs for at least 3 months. Molecular response was determined by chart review. Of 40 patients surveyed, 50% were enrolled in the POCP, and the POCP group had more African Americans than the non-POCP group. More patients in the POCP were satisfied with their care than in the non-POCP group (100% vs. 75%,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.